Mirum Pharmaceuticals, Inc. Common Stock

Day range

$81.16 – $82.91

Open

$81.76

Prev close

$80.39

Volume

190.37K

Market cap

$5.22B

Shares out

64.93M

P/E

—

P/S

8.45

P/B

-500.85

P/FCF

—

ROE

8253.8%

ROA

-82.3%

Debt/Equity

-71.97

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsOct 13, 2026

  On October 12, 2026, Mirum Pharmaceuticals, Inc. announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with ultra-rare cholestatic liver diseases, including biliary atresia ("BA"). The study met its primary endpoint and achieved statistical significance across all five prespecified secondary endpoints.

• Clinical trial resultsSep 28, 2026

  “At Week 24, mean total new HO lesion volume decreased by 3.2 cm3 in patients receiving zilurgisertib compared with an increase of 24.6 cm3 in placebo-treated patients. Treatment effects were maintained through Week 48 of the open-label extension.”

• Executive officer appointmentSep 8, 2026

  On September 8, 2026, Mirum Pharmaceuticals, Inc. announced that, on September 2, 2026, the Company's Board of Directors appointed Rob Myers, M.D., to succeed Joanne Quan, M.D., as the Company's Chief Medical Officer, effective upon Dr. Myers' beginning employment with the Company, which employment is expected to begin on September 21, 2026.

• Debt issuanceMay 18, 2026

  On May 15, 2026, Mirum Pharmaceuticals, Inc. (the "Company") issued $690.0 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2032 (the "Notes"), which includes the full exercise of the initial purchasers' option to purchase up to an additional $90.0 million aggregate principal amount of Notes. The Notes were issued pursuant to, and are governed by, an indenture (the "Indenture"), dated as of May 15, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee.

• Clinical trial resultsMay 4, 2026

  On May 4, 2026, Mirum Pharmaceuticals, Inc. (the "Company") announced the primary endpoint was met in the VISTAS Phase 2b study evaluating volixibat, an investigational oral ileal bile acid transporter ("IBAT") inhibitor, in patients with primary sclerosing cholangitis ("PSC"). In the primary analysis cohort, treatment with volixibat demonstrated a robust 2.72 point improvement in pruritus and a placebo-adjusted difference of 1.64 points in the primary endpoint (p<0.0001).

Days to cover

7.7

Short interest

6.99M

Avg volume

910.92K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
  positiveZacks Investment Research· Oct 13, 2026
• Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
  positiveZacks Investment Research· Sep 29, 2026
• Arcutis Expands Board of Directors with Appointment of Chris Peetz
  positiveGlobeNewswire Inc.· Jul 16, 2026
• Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
  neutralThe Motley Fool· Mar 20, 2026
• XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
  positiveGlobeNewswire Inc.· Mar 18, 2026